Bisphosphonate therapy in multiple myeloma: past, present, future

Area of Science:

• Oncology
• Pharmacology
• Bone Metabolism

Background:

• Multiple myeloma frequently causes debilitating bone disease, including osteolytic lesions and pathological fractures.
• These bone complications lead to pain, reduced performance status, and necessitate palliative treatments.
• Hypercalcemia is a significant clinical manifestation requiring targeted management.

Purpose of the Study:

• To evaluate the efficacy of bisphosphonates in ameliorating the bone disease consequences in multiple myeloma.
• To assess the role of bisphosphonates in managing hypercalcemia and skeletal-related events.
• To determine the current standing and future optimization of bisphosphonate therapy in multiple myeloma care.

Main Methods:

• Review of bisphosphonate mechanisms of action, primarily targeting osteoclast activity.
• Analysis of clinical data on oral clodronate, intravenous pamidronate, and zoledronic acid in myeloma patients.
• Consideration of cost-benefit analyses and current therapeutic guidelines.

Main Results:

• Bisphosphonates are the preferred therapy for hypercalcemia in multiple myeloma.
• Oral clodronate and intravenous pamidronate demonstrate efficacy in reducing skeletal-related events during long-term management.
• Zoledronic acid shows comparable effectiveness to pamidronate.

Conclusions:

• Bisphosphonate therapy is an integral component of care for multiple myeloma patients with bone disease.
• The potential antimyeloma activity of bisphosphonates remains an area for further investigation.
• Optimization of bisphosphonate therapy in multiple myeloma requires continued research.